Russian rider Alexandr Kolobnev has been cleared of intentional doping by the Court of Arbitration (CAS) for Sport after failing a drug test at the 2011 Tour de France, and will not be suspended from competition.
CAS heard Kolobnev's case after the Union Cycliste Internationale (UCI) appealed against the Russian Cycling Federation's (FVSR) decision not to suspend Kolobnev. The FVSR imposed a 1500 CHF (Just over £1,000) fine on Kolobnev and gave him a warning, but no suspension. The UCI sought a two-year ban and a heavier fine.
CAS ruled that the presence of banned diuretic hydrochlorothiazide (HCT) in Kolobnev's system was due to the use of medication for a long-term vascular condition, and not to artifically enhance his cycling performance.
The adjudication panel at CAS heard that Kolobnev had been taking a drug called 'Natural Kapillyaroprotector' to treat his condition, which is available over-the-counter in Russia. Tests on the drug showed that it contained HCT.
A CAS statement issued on Wednesday said: "The CAS Panel was satisfied that the use of the product 'Natural Kapillyaroprotector' was justified by medical reasons totally unrelated to sport performance: the product, recommended by Kolobnev's doctor in 2009, had been actually indicated to supplement the treatment of the vascular disease affecting the athlete, and not (as food supplement normally are) to help an athlete recover from physical effort or better prepare for a sporting performance."
Despite having no further fine or suspension added to his penalty, CAS ordered Kolobnev to pay the costs of the anti-doping hearing.
Kolobnev tested positive for HCT after stage five of the Tour last July and left the race. It was the only positive test of the event.
Kolobnev has not had his contract renewed with Katusha and is currently without a squad for 2012. He has not raced since leaving the Tour.
Kolobnev doping hearing set for February
UCI appeals Kolobnev's Tour de France dope case to CAS
Kolobnev avoids suspension for Tour de France doping positive
Kolobnev's Tour de France positive confirmed
Kolobnev tests positive at Tour de France
Thank you for reading 5 articles this month* Join now for unlimited access
Enjoy your first month for just £1 / $1 / €1
*Read 5 free articles per month without a subscription
Join now for unlimited access
Try first month for just £1 / $1 / €1
Nigel Wynn worked as associate editor on CyclingWeekly.com, he worked almost single-handedly on the Cycling Weekly website in its early days. His passion for cycling, his writing and his creativity, as well as his hard work and dedication, were the original driving force behind the website’s success. Without him, CyclingWeekly.com would certainly not exist on the size and scale that it enjoys today. Nigel sadly passed away, following a brave battle with a cancer-related illness, in 2018. He was a highly valued colleague, and more importantly, n exceptional person to work with - his presence is sorely missed.
Why is the UCI cracking down on number pockets at the Tour after it approved them six years ago?
Is the forthcoming ban on window number pockets really necessary? We ask Nopinz, the creators of the original 'Speedpocket', what the reasoning is behind the UCI's actions
By Hannah Bussey • Published
Five things to look out for during week one of the Tour de France
The racing is just a day away, and we're expecting fireworks
By Stephen Puddicombe • Published